Nek2 as a novel molecular target for the treatment of breast carcinoma

Cancer Science

Volumn 100, Issue 1, 2009, Pages 111-116

  Tsunoda, Nobuyuki ^a   Kokuryo, Toshio ^a   Oda, Koji ^a   Senga, Takeshi ^a   Yokoyama, Yukihiro ^a   Nagino, Masato ^a   Nimura, Yuji ^a   Hamaguchi, Michinari ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN KINASE NEK2; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AGAR MEDIUM; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CELL INVASION; CELL STRAIN MCF 7; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR VOLUME; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MICE; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, ESTROGEN; RNA, SMALL INTERFERING;

EID: 58149284063     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.01007.x     Document Type: Article

References (22)

1. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825-31.
2. Longo R, Torino F, Gasparini G. Targeted therapy of breast cancer. Curr Pharm Des 2007; 13: 497-517.
3. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235-44.
4. Fry AM, Meraldi P, Nigg EA. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J 1998; 17: 470-81.
5. Fry AM. The Nek2 protein kinase: A novel regulator of centrosome structure. Oncogene 2002; 21: 6184-94.
6. Fletcher L, Cerniglia GJ, Nigg EA, Yend TJ, Muschel RJ. Inhibition of centrosome separation after DNA damage: A role for Nek2. Radiat Res 2004; 162: 128-35.
7. Kokuryo T, Senga T, Yokoyama Y, Nagino M, Nimura Y, Hamaguchi M. Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma. Cancer Res 2007; 67: 9637-42.
8. Hayward DG, Clarke RB, Faragher AJ, Pillai MR, Hagan IM, Fry AM. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res 2004; 64: 7370-6.
9. de Vos S, Hofmann WK, Grogan TM et al. Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest 2003; 83: 271-85.
10. Hamaguchi M, Matsuyoshi N, Ohnishi Y, Gotoh B, Takeichi M, Nagai Y. p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system. Embo J 1993; 12: 307-14.
11. Tanimura Y, Kokuryo T, Tsunoda N et al. Tumor necrosis factor alpha promotes invasiveness of cholangiocarcinoma cells via its receptor, TNFR2. Cancer Lett 2005; 219: 205-13.
12. Mon NN, Hasegawa H, Thant AA et al. A role for focal adhesion kinase signaling in tumor necrosis factor-alpha-dependent matrix metalloproteinase-9 production in a cholangiocarcinoma cell line, CCKS1. Cancer Res 2006; 66: 6778-84.
13. Toi M, Nakamura S, Kuroi K et al. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 2008; 110 (3): 531-9.
14. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004; 10: 5769-76.
15. Aas T, Geisler S, Eide GE et al. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2003; 39: 438-46.
16. Conforti R, Boulet T, Tomasic G et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracycline-based chemotherapy: A biomarker study from two randomized trials. Ann Oncol 2007; 18: 1477-83.
17. Shao W, Brown M. Advances in estrogen receptor biology: Prospects for improvements in targeted breast cancer therapy. Breast Cancer Res 2004; 6: 39-52.
18. Yoshida N, Omoto Y, Inoue A et al. Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci 2004; 95: 496-502.
19. Weinstein IB. Cancer: Addiction to Oncogenes - the Achilles heal of cancer. Science 2002; 297 (5578): 63-4.
20. Moody SE, Perez D, Pan TC et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005; 8: 197-209.
21. D'Cruz CM, Gunther EJ, Boxer RB et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001; 7: 235-9.
22. Gunther EJ, Moody SE, Belka GK et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 2003; 17: 488-501.